Translation of "cgi" to Norwegian language:


  Examples (External sources, not reviewed)

Table 3 Summary of CGI c in Trial 1
Tabell 3 Sammendrag for CGI c i studie 1
In all three studies, INVEGA was superior to placebo on PSP and CGI S.
INVEGA var bedre enn placebo på PSP og CGI S i alle tre studiene.
Response defined as decrease from baseline in PANSS Total Score 30 and CGI C Score 2
Respons definert som reduksjon fra utgangsnivå i PANSS totalscore 30 og CGI C score 2
Additionally, lurasidone was superior to placebo on the predefined secondary endpoint Clinical Global Impression Severity (CGI S) scale.
I tillegg var lurasidon bedre enn placebo på det predefinerte sekundære endepunktet Clinical Global Impression Sverity (CGI S) skalaen.
Adjunctive aripiprazole demonstrated superiority over placebo on the secondary outcome measure, CGI BP Severity of Illness score (mania).
Tilleggsbehandling med aripiprazol viste fortrinn i forhold til placebo på det sekundære endepunktet, CGI BP score for alvorlighetsgrad av sykdom (mani).
Predefined secondary endpoints included the Personal and Social Performance (PSP) scale and the Clinical Global Impression Severity (CGI S) scale.
Forhåndsdefinerte sekundære endepunkter omfattet PSP (Personal and Social Performance) skala og CGI S (Clinical Global Impression Severity) skala.
The changes from baseline in the International RLS Rating Scale (IRLS) and CGI item 1 (severity of illness) were primary efficacy parameters.
Endringene fra baseline på IRLS skalaen ( International Restless Legs Syndrome Rating Scale ) og CGI I (alvorlighetsgrad av sykdommen) var primære effektparametre.
No difference was observed for pramipexole as compared to placebo for either the primary endpoint or for any of the secondary efficacy endpoints including YGTSS total score, Patient Global Impression of Improvement (PGI I), Clinical Global Impression of Improvement (CGI I), or Clinical Global Impressions of Severity of Illness (CGI S).
Ingen endringer ble observert i pramipexolgruppen sammenlignet med placebogruppen verken for det primære endepunkt eller for noen av de sekundære effektendepunktene inkludert YGTSS total score, Patient Global Impression of Improvement (PGI I), Clinical Global Impression of Improvement (CGI I) eller Clinical Global Impressions of Severity of Illness (CGI S).
No difference was observed for pramipexole as compared to placebo for either the primary endpoint or for any of the secondary efficacy endpoints including YGTSS total score, Patient Global Impression of Improvement (PGI I), Clinical Global Impression of Improvement (CGI I), or Clinical Global Impressions of Severity of Illness (CGI S).
Ingen endringer ble observert i pramipexolgruppen sammenlignet med placebogruppen verken for det primære endepunkt eller for noen av de sekundære effektendepunktene, inkludert YGTSS total score, Patient Global Impression of Improvement (PGI I), Clinical Global Impression of Improvement (CGI I) eller Clinical Global Impressions of Severity of Illness (CGI S).
CGI I responder rates (improved, very much improved) were 51.2 and 72.0 for placebo and pramipexole, respectively (difference 20 CI 95 8.1 31.8 , p lt 0.0005).
CGI I responder rates (bedret, betydelig bedret) var 51,2 og 72,0 for henholdsvis placebo og pramipexol (forskjell 20 KI 95 8,1 31,8 , p lt 0,0005).
Efficacy was also evaluated by calculation of treatment response (defined as decrease in PANSS Total Score 30 and CGI C Score 2) as a secondary endpoint.
Effekten ble også evaluert ved beregning av behandlingsrespons (definert som reduksjon i PANSS totalscore 30 og CGI C score 2) som et sekundært endepunkt.
CGI I responder rates (much improved, very much improved) were 43.0 and 67.5 for placebo and rotigotine respectively (difference 24.5 CI 95 14.2 34.8 , p lt 0.0001).
CGI I responsrate (stor forbedring, svært stor forbedring) var 43,0 og 67,5 for henholdsvis placebo og rotigotin (forskjell 24,5 , KI95 14,2 , 34,8 , p lt 0,0001).
The mean change from baseline in the Restless Legs Syndrome Rating Scale (IRLS) and the Clinical Global Impression Improvement (CGI I) were the primary efficacy outcome measures.
De primære effektparametrene var gjennomsnittlig endring fra baseline i Restless Legs Syndrome Rating Scale (IRLS) og Clinical Global Impression Improvement (CGI I).
This was supported by clinical relevance as demonstrated by the proportions of responders and remitters and the improvement in the Clinical Global Impression Global Improvement (CGI I) score.
Dette ble understøttet av klinisk relevans vist ved andel pasienter som responderte og pasienter som oppnådde remisjon, samt bedring i Clinical Global Impression Global Improvement (CGI I) skår.
Vortioxetine was statistically significantly better than agomelatine as measured by improvement in the MADRS total score and supported by the clinical relevance as demonstrated by the proportions of responders and remitters and improvement in the CGI I.
Vortioksetin var statistisk signifikant bedre enn agomelatin målt ved bedring i MADRS totalskår og understøttet av klinisk relevans vist ved andelen respondere, remittere og ved forbedring i CGI I.
The primary measures of efficacy were changes in excessive daytime sleepiness as measured by the Epworth Sleepiness Scale (ESS), and the change in the overall severity of the patient s narcolepsy symptoms as assessed by the investigator using the Clinical Global Impressions of Change (CGI c) measure.
De primære effektparametrene var endringer i ekstrem søvnighet på dagtid målt ved bruk av Epworth Sleepiness Scale (ESS), og endringen i generell alvorlighet i pasientens narkolepsisymptomer, vurdert av utprøveren ved bruk av Clinical Global Impressions of Change (CGI c).
Superiority of MIRAPEXIN prolonged release tablets over placebo was demonstrated after 18 weeks of treatment on both the primary (UPDRS Parts II III score) and the key secondary (CGI I and PGI I responder rates) efficacy endpoints in a double blind placebo controlled trial including a total of 539 patients with early Parkinson s disease.
Etter 18 ukers behandling i en dobbeltblind, placebokontrollert studie som inkluderte totalt 539 pasienter med Parkinsons sykdom i tidlig fase, hadde MIRAPEXIN depottabletter bedre effekt enn placebo både på primære (UPDRS Parts II III score) og de viktigste sekundære (CGI I og PGI I responderrater) effektendepunktene.
Superiority of pramipexole prolonged release tablets over placebo was demonstrated after 18 weeks of treatment on both the primary (UPDRS Parts II III score) and the key secondary (CGI I and PGI I responder rates) efficacy endpoints in a double blind placebo controlled trial including a total of 539 patients with early Parkinson s disease.
Etter 18 ukers behandling i en dobbeltblind, placebokontrollert studie som inkluderte totalt 539 pasienter med Parkinsons sykdom i tidlig fase, hadde pramipexol depottabletter bedre effekt enn placebo både på primære (UPDRS Parts II III score) og de viktigste sekundære (CGI I og PGI I
Superiority of pramipexole prolonged release tablets over placebo was demonstrated after 18 weeks of treatment on both the primary (UPDRS Parts II III score) and the key secondary (CGI I and PGI I responder rates) efficacy endpoints in a double blind placebo controlled trial including a total of 539 patients with early Parkinson s disease.
Etter 18 ukers behandling i en dobbeltblind, placebokontrollert studie som inkluderte totalt 539 pasienter med Parkinsons sykdom i tidlig fase, hadde pramipexol depottabletter bedre effekt enn placebo både på primære (UPDRS Parts II III score) og de viktigste sekundære (CGI I og PGI I responderrater) effektendepunktene.
Superiority of SIFROL prolonged release tablets over placebo was demonstrated after 18 weeks of treatment on both the primary (UPDRS Parts II III score) and the key secondary (CGI I and PGI I responder rates) efficacy endpoints in a double blind placebo controlled trial including a total of 539 patients with early Parkinson s disease.
Etter 18 ukers behandling i en dobbeltblind, placebokontrollert studie som inkluderte totalt 539 pasienter med Parkinsons sykdom i tidlig fase, hadde SIFROL depottabletter bedre effekt enn placebo både på primære (UPDRS Parts II III score) og de viktigste sekundære (CGI I og PGI I responderrater) effektendepunktene.

 

Related searches: Cgi - Cgi-i - Cgi-c - Cgi, Article 262, - Cgi Artist - Doing Cgi - Article 209 Cgi - Cgi Application Program - Isapi And Cgi Restrictions - Cgi-bin -